NCEL

NewcelX Ltd.

3.10 USD

Last updated Oct 7, 19:30 UTC

Yesterday HIGH

$3.17

Yesterday LOW

$2.92

52w HIGH

$19.8

52w LOW

$1.83

EPS

-2.16

PE

-1.44

Next Earnings

Oct 20, 2026

Overview News Government Trades Fundamentals

NewcelX Ltd. stock is down -4.62% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 5 October’s closed higher than September.

Benzinga Newsdesk

Thu Apr 30, 2026

NewcelX FY EPS $(2.16) Up From $(2.43) YoY

NewcelX (NASDAQ:NCEL) reported quarterly losses of $(2.16) per share. This is a 11.11 percent increase over losses of $(2.43) per share from the same period last year.
Vandana Singh

Thu Apr 30, 2026

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
Benzinga Newsdesk

Thu Apr 30, 2026

EXCLUSIVE: NewcelX Expects Expanded Strategic Development Collaborations For Diabetes Drug In 2026

Outlook for 2026The Company expects 2026 to be a year of accelerated execution, including: Advancing NCEL-101 toward key IND-enabling milestones Expanding strategic development collaborations Pursuing additional
Benzinga Insights

Wed Apr 29, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Thu Apr 23, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Newsdesk

Mon Apr 20, 2026

NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection

NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that
Benzinga Insights

Wed Apr 8, 2026

9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights

Tue Apr 7, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Newsdesk

Wed Apr 1, 2026

NewcelX shares are trading higher after the company announced it entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share.
Benzinga Newsdesk

Wed Apr 1, 2026

NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes programZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical